Melatonin for Prevention of Post Stroke Delirium

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04122599

Enrollment

2000

Registered

2019-10-10

Start date

2017-07-01

Completion date

2019-12-31

Last updated

2019-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Stroke Delirium

Keywords

Melatonin

Brief summary

Post stroke delirium is prevalent in 10-30% of all stroke patients. We aimed to investigate wether Melatonin 2mg may prevent post stroke delirium.

Interventions

DRUGMelatonin

Melatonin for prevent post stroke delirium

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Healthy volunteers

Inclusion criteria

* all patients with stroke, TIA or ICH admitted to our stroke unit or intemdiate care unit * Stroke / ICH /TIA onset \<= 48h

Exclusion criteria

* RASS \<=4 * severe dementia, psychosis or depression

Design outcomes

Primary

Measure	Time frame
Change of delir prevalence	3months

Secondary

Measure	Time frame
Change of hospital stay	3months
Change of antipsychotic drug administration	3 months
Changed stay on stroke unit and/or intermediate care	3 months

Countries

Germany

Contacts

Primary ContactAnnerose Mengel, MD

annerose.mengel@med.uni-tuebingen.de004970712985354

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026